Haiqi He

Guangdong Provincial Key Laboratory Of New Drug Screening, NMPA Key Laboratory For Research And Evaluation Of Drug Metabolism
Guangzhou, 510515, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Discovery of the first dual PD-L1/JAK inhibitor with enhanced in vivo antitumor immunity.

Discovery of the first dual PD-L1/JAK inhibitor with enhanced in vivo antitumor immunity.

Journal: European journal of medicinal chemistry

Published: October 16, 2025

Discovery and Crystallography Study of Novel Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment.

Discovery and Crystallography Study of Novel Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment.

Journal: Journal of medicinal chemistry

Published: June 16, 2025

Discovery of Dual PD-L1/HDAC3 Inhibitors for Tumor Immunotherapy.

Discovery of Dual PD-L1/HDAC3 Inhibitors for Tumor Immunotherapy.

Journal: Journal of medicinal chemistry

Published: April 15, 2025

Discovery of Novel and Highly Potent Dual PD-L1/Histone Deacetylase 6 Inhibitors with Favorable Pharmacokinetics for Cancer Immunotherapy.

Discovery of Novel and Highly Potent Dual PD-L1/Histone Deacetylase 6 Inhibitors with Favorable Pharmacokinetics for Cancer Immunotherapy.

Journal: Journal of medicinal chemistry

Published: February 20, 2025

Recent progress in the development of peptide-drug conjugates (PDCs) for cancer therapy.

Recent progress in the development of peptide-drug conjugates (PDCs) for cancer therapy.

Journal: European journal of medicinal chemistry

Published: November 04, 2024

Targeting the STAT3 pathway with STAT3 degraders.

Targeting the STAT3 pathway with STAT3 degraders.

Journal: Trends in pharmacological sciences

Published: June 27, 2024

Discovery of Novel Small-Molecule-Based Potential PD-L1/EGFR Dual Inhibitors with High Druggability for Glioblastoma Immunotherapy.

Discovery of Novel Small-Molecule-Based Potential PD-L1/EGFR Dual Inhibitors with High Druggability for Glioblastoma Immunotherapy.

Journal: Journal of medicinal chemistry

Published: May 13, 2024

Discovery of novel resorcinol biphenyl ether-based macrocyclic small molecules as PD-1/PD-L1 inhibitors with favorable pharmacokinetics for cancer immunotherapy.

Discovery of novel resorcinol biphenyl ether-based macrocyclic small molecules as PD-1/PD-L1 inhibitors with favorable pharmacokinetics for cancer immunotherapy.

Journal: Bioorganic chemistry

Published: June 07, 2023

Showing 1-8 of 8

Last Updated: 09/26/2026